GO:1900121 negative regulation of receptor binding: Signaling Brake Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900121 (negative regulation of receptor binding) describes any process that stops, prevents, or reduces the binding of a protein or other molecule to a receptor.
• This term is a biological_process node that captures an upstream regulatory step in cell signaling, distinct from downstream events such as receptor internalization or kinase inhibition.
• Key molecular players include decoy ligands, soluble receptor ectodomains, and intracellular proteins such as RGS2/RGS4 that modulate receptor-G protein coupling.
• Dysregulation of negative regulation of receptor binding contributes to endocrine disorders, cancer, and neurological conditions.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect the causal role of genes mediating this process.
• EDITGENE provides end-to-end CRISPR services, including library screening and bioinformatics, to study negative regulation of receptor binding in disease models.
Description
Negative regulation of receptor binding (GO:1900121) is a biological process that stops, prevents, or reduces the frequency, rate, or extent of a protein or other molecule binding to a receptor. This regulatory mechanism is fundamental to controlling signal transduction, ensuring that cells respond appropriately to hormones, neurotransmitters, and cytokines. For researchers, understanding this process is critical because its dysregulation can lead to diseases ranging from cancer to metabolic disorders. The term encompasses diverse molecular strategies, including decoy receptors, soluble ligand traps, and intracellular modulators that alter receptor availability or affinity. By studying GO:1900121, scientists can identify therapeutic targets and develop interventions that fine-tune receptor signaling.
negative regulation of receptor binding At A Glance
| GO ID | GO:1900121 |
|---|---|
| GO term | negative regulation of receptor binding |
| Ontology | biological_process |
| Synonym | down regulation of receptor binding; inhibition of receptor ligand; downregulation of receptor binding |
| Major function | Attenuation of receptor-ligand interaction to modulate signal transduction |
| Related processes | Receptor signaling, ligand sequestration, decoy receptor activity |
| Disease relevance | Endocrine disorders, cancer, neurological conditions |
| Experimental approaches | CRISPR KO, point mutation, knock-in, overexpression, library screening |
What Is GO:1900121?
In our own words, negative regulation of receptor binding refers to any cellular process that decreases the interaction between a signaling molecule (such as a hormone, growth factor, or neurotransmitter) and its specific receptor. This can occur through mechanisms like ligand sequestration, receptor decoy formation, or allosteric modulation, ultimately reducing downstream signaling.
Why Is negative regulation of receptor binding Important in Cell Biology?
Negative regulation of receptor binding is a cornerstone of cellular homeostasis, preventing excessive or inappropriate signaling that can drive pathological states. For example, dysregulated receptor binding underlies hormone-dependent cancers and metabolic diseases. Understanding this process provides opportunities for therapeutic intervention, such as using decoy receptors or small molecules to block ligand-receptor interactions.
• Controls signal transduction to prevent overstimulation by hormones and neurotransmitters.
• Involved in endocrine disorders such as hyperthyroidism and diabetes.
• Plays a role in cancer progression by modulating growth factor receptor binding.
• Affects neurological functions through opioid and adrenergic receptor regulation.
• Provides targets for drug development, including decoy receptors and monoclonal antibodies.
• Essential for immune response regulation via cytokine signaling.
• Contributes to circadian rhythm regulation through adrenergic receptor signaling.
• Can be studied using CRISPR-based gene editing to dissect causal mechanisms.
What Happens During negative regulation of receptor binding?
Ligand Sequestration and Decoy Receptors
In simple terms: The cell uses decoy molecules to soak up ligands before they can reach real receptors.
One major mechanism of negative regulation of receptor binding involves the production of soluble decoy receptors or ligand-binding proteins that sequester ligands away from functional receptors. For instance, the glucagon receptor undergoes negative regulation through a decoy mechanism that prevents glucagon binding, thereby reducing downstream cAMP signaling. Similarly, cytokine signaling is negatively regulated by soluble receptors that act as traps.
Intracellular Modulation of Receptor Availability
In simple terms: Inside the cell, proteins can change how receptors are presented or recycled, reducing their ability to bind ligands.
Intracellular proteins such as RGS2 and RGS4 modulate κ-opioid receptor signaling by affecting receptor-G protein coupling, which indirectly reduces ligand binding efficiency. Additionally, RIP140 negatively regulates hormone signaling by competing with coactivators, thereby reducing the binding of hormones to their nuclear receptors.
Allosteric and Conformational Changes
In simple terms: The receptor's shape can be altered so that ligands no longer fit or bind effectively.
Negative regulation can occur through allosteric changes in receptor conformation that lower affinity for ligands. For example, nefiracetam negatively regulates the opioid receptor-G protein-Ca2+ channel pathway, likely by inducing conformational changes that reduce ligand binding. Such allosteric modulation is a key theme in receptor pharmacology.
Transcriptional and Post-translational Control
In simple terms: The cell can reduce the number of receptors on its surface or modify them so they bind less.
Transcriptional downregulation of receptor genes or post-translational modifications like phosphorylation can decrease receptor binding. For instance, adrenergic receptor signaling in osteoblasts regulates clock genes, and negative regulation of this pathway involves reduced receptor availability. Similarly, thyrotropin receptor function is tightly controlled by negative regulatory mechanisms that affect ligand binding.
Key Genes Involved in GO:1900121 negative regulation of receptor binding
The following genes and proteins are experimentally implicated in negative regulation of receptor binding, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RGS2 | Modulates κ-opioid receptor signaling | Regulates receptor-G protein coupling |
| RGS4 | Modulates κ-opioid receptor signaling | Regulates receptor-G protein coupling |
| RIP140 | Negative regulation of hormone signaling | Competes with coactivators |
| GCGR | Glucagon receptor | Negative regulation via decoy mechanism |
| TSHR | Thyrotropin receptor | Regulated by negative feedback |
| OPRK1 | κ-opioid receptor | Target of RGS proteins |
| ADRB2 | Adrenergic receptor | Regulates clock genes in osteoblasts |
| IL6ST | Cytokine signaling | Negatively regulated by SOCS proteins |
| SOCS1 | Cytokine signaling inhibitor | Negative regulation of cytokine receptor binding |
| SOCS3 | Cytokine signaling inhibitor | Negative regulation of cytokine receptor binding |
| VOSORITIDE | CNP analog | Used in achondroplasia, modulates receptor binding |
| Nefiracetam | Nootropic | Negatively regulates opioid receptor pathway |
| CNP | C-type natriuretic peptide | Ligand for NPR-B, regulated in growth |
| FGFR3 | Fibroblast growth factor receptor 3 | Target of vosoritide in achondroplasia |
| LEPR | Leptin receptor | Negatively regulated in obesity |
| ESR1 | Estrogen receptor | Negatively regulated by RIP140 |
| AR | Androgen receptor | Negatively regulated by RIP140 |
How Is negative regulation of receptor binding Regulated?
Negative regulation of receptor binding is itself controlled by various cellular pathways. For example, cytokine signaling is negatively regulated by SOCS proteins, which are induced by cytokines and then feedback to inhibit receptor binding. Similarly, RGS proteins are regulated by GPCR activation and modulate receptor-G protein coupling. Hormone signaling is negatively regulated by RIP140, whose expression is controlled by nuclear receptors.
negative regulation of receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGFR3 | Achondroplasia | Knock-in mouse model with FGFR3 mutation |
| RIP140 | Breast cancer | Knockout mice and cancer cell lines |
| RGS2/RGS4 | Opioid addiction | Knockout mice and neuronal cultures |
| TSHR | Graves' disease | Knock-in and overexpression models |
| GCGR | Type 2 diabetes | Knockout and point-mutation models |
Achondroplasia and Skeletal Dysplasias
In achondroplasia, overactive FGFR3 signaling due to excessive ligand binding leads to impaired bone growth. Vosoritide, a CNP analog, acts by negatively regulating receptor binding at the FGFR3 pathway, thereby promoting bone growth.
Cancer and Hormone-Dependent Tumors
Negative regulation of receptor binding is often disrupted in hormone-dependent cancers. For instance, RIP140 negatively regulates estrogen and androgen receptor signaling, and its loss can lead to enhanced hormone binding and tumor progression.
Neurological and Psychiatric Disorders
Dysregulation of opioid and adrenergic receptor binding contributes to pain, addiction, and mood disorders. RGS proteins and nefiracetam modulate these pathways, highlighting the therapeutic potential of targeting negative regulation of receptor binding.
Endocrine and Metabolic Disorders
Thyrotropin receptor and glucagon receptor signaling are tightly controlled by negative regulation of receptor binding. Disruption of these mechanisms can lead to hyperthyroidism or diabetes.
From negative regulation of receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate receptor binding? | CRISPR knockout in cell lines |
| What is the effect of a point mutation in the receptor on ligand binding? | CRISPR point mutation knock-in |
| How does overexpression of a decoy receptor affect signaling? | CRISPR overexpression models |
| Can we screen for novel regulators of receptor binding? | CRISPR library screening |
| What is the structural basis of negative regulation? | Tagged knock-in for imaging |
| How does negative regulation affect disease progression? | Patient-derived organoids with CRISPR edits |
How to Study the negative regulation of receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function loss | Identify negative regulators of receptor binding |
| CRISPR point mutation | Specific amino acid changes | Study receptor-ligand interface |
| CRISPR knock-in | Tagged or mutant receptor | Visualize receptor trafficking |
| Overexpression | Gain-of-function | Test decoy receptors |
| RNA-seq | Transcriptional changes | Measure receptor expression |
| Proteomics | Protein interactions | Identify binding partners |
| SPR | Binding affinity | Quantify ligand-receptor kinetics |
| FRET/BRET | Real-time binding | Monitor dynamic regulation |
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate receptor binding. For example, screens targeting GPCR pathways have uncovered RGS proteins and decoy receptors.
Biochemical Binding Assays
Radioligand binding assays and surface plasmon resonance (SPR) measure the affinity and kinetics of ligand-receptor interactions, allowing quantification of negative regulation.
Transcriptomics and Proteomics
RNA-seq and mass spectrometry can reveal changes in receptor expression and post-translational modifications that affect binding.
Imaging and Live-Cell Analysis
Fluorescence resonance energy transfer (FRET) and BRET sensors enable real-time monitoring of receptor-ligand binding in living cells, providing dynamic insights into negative regulation.
How CRISPR Can Be Used to Study GO:1900121 negative regulation of receptor binding
Knockout
CRISPR knockout of candidate genes such as RGS2, RGS4, or RIP140 can reveal their role in negative regulation of receptor binding. For example, knocking out RGS proteins enhances opioid receptor signaling, confirming their negative regulatory function.
Point Mutation
Introducing point mutations in receptor genes (e.g., FGFR3) can mimic disease-associated variants and test their impact on ligand binding. This approach is valuable for studying achondroplasia and cancer.
Knock-in
Knock-in of tagged receptors or decoy proteins allows visualization and quantification of receptor binding in vivo. This is useful for tracking dynamic regulation.
Overexpression
Overexpressing decoy receptors or negative regulators can suppress receptor binding and downstream signaling, providing a gain-of-function model to study disease mechanisms.
How EDITGENE Supports negative regulation of receptor binding Research
Researchers studying negative regulation of receptor binding-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated. EDITGENE provides the CRISPR tools and services to establish causality through precise genome editing.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of receptor binding research.
Frequently Asked Questions About negative regulation of receptor binding
What is negative regulation of receptor binding?
It is a biological process that stops, prevents, or reduces the binding of a protein or other molecule to a receptor, as defined by GO:1900121.
What genes are involved in negative regulation of receptor binding?
Key genes include RGS2, RGS4, RIP140, SOCS1, SOCS3, and decoy receptors like soluble cytokine receptors.
How does negative regulation of receptor binding affect disease?
Dysregulation can lead to cancer, endocrine disorders, and neurological conditions by altering signal transduction.
What experimental models are used to study negative regulation of receptor binding?
CRISPR knockout, point mutation, knock-in, overexpression, and library screening are commonly used.
Can CRISPR be used to study negative regulation of receptor binding?
Yes, CRISPR enables precise gene editing to dissect causal roles of specific genes in this process.
What is the role of RGS proteins in negative regulation of receptor binding?
RGS proteins modulate G protein-coupled receptor signaling, indirectly reducing ligand binding efficiency.
How does vosoritide relate to negative regulation of receptor binding?
Vosoritide is a CNP analog that negatively regulates FGFR3 signaling by reducing ligand binding, used in achondroplasia.
What methods measure negative regulation of receptor binding?
Binding assays, SPR, FRET/BRET, and CRISPR screens are standard methods.
What diseases are associated with defective negative regulation of receptor binding?
Achondroplasia, hormone-dependent cancers, opioid addiction, and diabetes.
How can EDITGENE help study negative regulation of receptor binding?
EDITGENE provides CRISPR cell models, library screening, and bioinformatics to investigate this process.
Conclusion
Negative regulation of receptor binding (GO:1900121) is a vital biological process that fine-tunes signal transduction and prevents pathological overactivation. Understanding its molecular players and mechanisms offers therapeutic opportunities for a range of diseases. CRISPR-based models and EDITGENE services empower researchers to dissect this process with precision.
References
- 1. Duggan S. 2021. Vosoritide: First Approval.. Drugs 81(17):2057-2062 PMID: 34694597
- 2. Hirai T. 2018. Regulation of Clock Genes by Adrenergic Receptor Signaling in Osteoblasts.. Neurochem Res 43(1):129-135 PMID: 28752422
- 3. Papakonstantinou MP et al.. 2015. RGS2 and RGS4 proteins: New modulators of the κ-opioid receptor signaling.. Cell Signal 27(1):104-14 PMID: 25289860
- 4. Koth CM et al.. 2012. Molecular basis for negative regulation of the glucagon receptor.. Proc Natl Acad Sci U S A 109(36):14393-8 PMID: 22908259
- 5. Yasukawa H et al.. 2000. Negative regulation of cytokine signaling pathways.. Annu Rev Immunol 18:143-64 PMID: 10837055
- 6. Yoshii M et al.. 2004. Negative regulation of opioid receptor-G protein-Ca2+ channel pathway by the nootropic nefiracetam.. Ann N Y Acad Sci 1025:389-97 PMID: 15542741
- 7. Augereau P et al.. 2006. Negative regulation of hormone signaling by RIP140.. J Steroid Biochem Mol Biol 102(1-5):51-9 PMID: 17056252
- 8. Kohn LD et al.. 1995. The thyrotropin receptor.. Vitam Horm 50:287-384 PMID: 7709602
